Research Article

Intravenous Cyclophosphamide Therapy for Anti-IFN-Gamma Autoantibody-Associated Mycobacterium abscessus Infection

Ploench Chetchotisakd, Siriluck Anunnatsiri, Ratanavee Nanagara, Arnone Nithichanon, and Ganjana Lertmemongkolchai

1Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
2Division of Rheumatology, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
3Cellular and Molecular Immunology Unit, Centre for Research and Development of Medical Diagnostic Laboratories (CMDL), Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen, Thailand

Correspondence should be addressed to Ploench Chetchotisakd; ploencha@kku.ac.th

Received 14 August 2018; Accepted 7 November 2018; Published 30 December 2018

Academic Editor: Theresa Hautz

Copyright © 2018 Ploench Chetchotisakd et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. Anti-interferon-gamma (IFN-\(\gamma\)) autoantibodies are increasingly recognized as a cause of adult-onset immunodeficiency (AOID) worldwide [1–19]. These patients are susceptible to various intracellular pathogens especially nontuberculous mycobacteria (NTM). The majority of patients have a persistent NTM infection and require long-term antimycobacterial therapy [20]. Some patients infected with rapidly growing mycobacteria (RGM) have recurrent disease despite continuous oral antimycobacterial treatment and need hospitalization for parenteral imipenem. Various adjunctive therapies have been used to treat patients with anti-IFN-\(\gamma\) autoantibodies [3, 4, 21–25], including B cell depletion therapy with rituximab which has attracted much attention. Owing to economic constraints, rituximab is not accessible through the Thai National Health Insurance program for off-label treatment.

Cyclophosphamide is an alkylating agent affecting depletion of both B and T cells, hence reducing the production of pathogenic autoantibodies. Intravenous cyclophosphamide (IVCY) has been used successfully as an induction therapy for severe lupus nephritis, either 6 monthly pulses of IVCY
(NIH regimen) [26] or 6 pulses of lower-dose IVCY every 2 weeks (Euro-Lupus Nephritis Trail) [27]. The low-dose regimen was found to be associated with half as many severe infections as compared to the high-dose regimen, and long-term outcomes did not differ at the 10-year follow-up [28]. Currently, IVCY has been used as a standard regimen particularly for severe autoimmune and autoinflammatory diseases such as systemic lupus erythematosus (SLE) [29–32], active alveolitis from systemic sclerosis [33–35], antineutrophil cytoplasmic antibodies (ANCA-) associated primary vasculitis syndrome [36–38], and other autoimmune diseases [39–44].

Plasmapheresis followed by pulse cyclophosphamide has been successfully treated in an AOID patient with recurrent MAC infection [21]. Herein, we report the use of immunotherapy with intravenous cyclophosphamide (IVCY) in 8 AOID patients with a high titer of anti-IFN-γ autoantibodies who had progressive refractory M. abscessus infection needing frequent hospitalization for parenteral antibiotics.

2. Methods

2.1. Ethics. This study is a retrospective study and has been approved by our ethics committee (HE601199).

2.2. Patients and Immunotherapy. All patients were seen at Srinagarind Hospital, a tertiary care university hospital. The standard regimen for treating AOID patients infected with RGM is a combination of oral antimycobacterial agents, mostly macrolides and fluoroquinolones. If they have progressive disease—despite being continuously on oral antimycobacterial treatment—they will be hospitalized for parenteral antibiotic treatment (i.e., particularly imipenem for 2–4 weeks).

We included patients who received ≥3 courses of parenteral antibiotics within 12 months and who received pulse IVCY. The regimen consists of methylprednisolone 1,000 mg intravenous on the last day of parenteral antibiotics followed by oral prednisolone 30 mg/day and IVCY 400 mg every 2 weeks for 6 cycles, then IVCY 400 mg every 4–6 weeks for 3 cycles plus oral prednisolone 15 mg/day, then IVCY 400 mg every 8–12 weeks for 3 cycles and oral prednisolone 10 mg/day, and then IVCY 400 mg every 12 weeks and oral prednisolone 5 mg/day until 2 years of therapy was completed. All patients received a combination of oral antimycobacterial treatment continuously.

2.3. Clinical Monitoring. Patients underwent routine safety monitoring during the IVCY therapy, including complete blood count with differentials, urine analysis, and renal and hepatic function chemistries. We also monitored their anti-IFN-γ titer. Disease activity was assessed by observing clinical signs and evidence of active infection on computed tomography, pathology, culture, or smear as indicated. Treatment and clinical data were collected by review of chart records.

2.4. Determination of IFN-γ Autoantibody Titers. A method for determining anti-IFN-γ autoantibody titer was previously described [20, 45]. Briefly, a 96-well polystyrene plate (Nunc) was precoated with 100 μl of anti-human IFN-γ capture antibody (BD Biosciences) overnight at 4°C. On the day of the experiment, the precoated plate was washed 3 times with 0.05% Tween20 in phosphate-buffered saline (PBS) and then blocked with 200 μl of 10% fetal bovine serum in PBS for 2 h at room temperature. Meanwhile, plasma samples were diluted with 300 pg/ml of recombinant human IFN-γ at 1:100, 1:1,000, 1:5,000, 1:10,000, 1:50,000, 1:100,000, 1:200,000, 1:400,000, 1:800,000, and 1:1,600,000 before being incubated at 37°C for 1 h. The preincubated diluted plasma samples (100 μl) were added to the plate and incubated at room temperature for 1 h. After washing 5 times with 0.05% Tween20-PBS, a 100 μl mixture of horseradish peroxidase (HRP), tagged streptavidin, and biotinylated anti-human IFN-γ detection antibody (BD Biosciences) was added to the plate and incubated at room temperature for 1 h. The plate was washed 7 times before adding 100 μl of tetramethylbenzenediyl (TMB) substrate (BD Biosciences), which was incubated at room temperature for 15 min. The reaction was stopped by adding 25 μl of 2 N H₂SO₄. Absorbance was measured at 450/570 nm by spectrophotometry.

The level of detectable human IFN-γ was calculated according to the standard curve from each plate. The percentage of neutralizing IFN-γ from each diluted plasma sample was calculated according to the equation below. The highest plasma dilution that resulted in ≥50% neutralization of the IFN-γ was considered a positive titer.

\[
\text{%neutralizing IFN-γ} = \left(1 - \frac{\text{detectable IFN-γ}}{300}\right) \times 100
\]

GraphPad Prism version 6 (GraphPad) was used for the statistical analysis. Statistical significance was determined using ANOVA with Dunnett’s multiple comparisons test. All the data used to support the findings of this study are included within the article.

3. Results

3.1. Patients. There were 8 AOID patients who met the criteria and received pulse IVCY between January 2011 and December 2015. All of the patients had M. abscessus lymphadenitis along with other organ involvements. All but two patients were coinfected with other opportunistic infections. All of the patients had progressive mycobacterial infection for over 10–48 months. The median NTM infection was 17 months before IVCY therapy. The patients received 3–6 courses of parenteral antimicrobial (mostly imipenem) within 12 months prior to the IVCY.

Table 1 summarizes the clinical data and outcomes of disseminated M. abscessus-infected patients treated with IVCY. Patients received 5–25 cycles of IVCY (median, 17 cycles). There were no serious laboratory test results related to cyclophosphamide during the IVCY therapy. Patient #1 received 5 courses of IVCY and then was lost to follow-up: he had died at home some 3 months after we lost contact with him. (Patient #1 was censored from the analysis.) Among the 7 evaluable cases, 5 had favorable outcomes: 2 (patients #2
| Patient no. | Age/sex | Organ involvement | Treatment duration before IVCY (month) | Other opportunistic infection | Oral antibiotic | Parenteral antibiotic prior to IVCY/duration (week) | No. of IVCY cycle received | Initial IFN-γ Ab titer | IFN-γ Ab titer at the end of treatment | Follow-up after IVCY (month) | Outcome |
|------------|---------|-------------------|----------------------------------------|-----------------------------|----------------|-----------------------------------------------|--------------------------|----------------|---------------------------------|--------------------------|---------|
| 1          | 52/M    | Lymph nodes, lung, spleen | 19 | Tuberculosis lung, Herpes zoster, penicilliosis | Clarithromycin, ciprofloxacin | (1) Cefoxitin/2 (2) Imipenem/2 (3) Imipenem/4 (4) Imipenem/4 | 5 | 1 : 100,000 | 1 : 50,000 | | Not applicable | Unevaluable: lost to follow-up and died 3 months later |
| 2          | 54/M    | Lymph nodes, lung | 15 | None | Clarithromycin, ciprofloxacin | (1) Imipenem/2 (2) Imipenem/4 (3) Imipenem/4 | 14 | 1 : 200,000 | 1 : 5,000 | 57 | | Response: cured with discontinued NTM treatment |
| 3          | 57/M    | Lymph nodes, lung, liver | 10 | Tuberculosis lung | Azithromycin, ciprofloxacin | (1) Imipenem/4 (2) Imipenem/4 (3) Imipenem/4 | 16 | 1 : 200,000 | 1 : 1,000 | 44 | | Response: cured with discontinued NTM treatment |
| 4          | 41/M    | Lymph nodes, nasal septum | 19 | Melioidosis | Clarithromycin, ciprofloxacin | (1) Imipenem/2 (2) Imipenem/4 (3) Imipenem/4 (4) Imipenem/4 | 17 | 1 : 200,000 | 1 : 1,000 | 60 | | Response: stable on NTM treatment without hospitalization for parenteral antibiotic |
| 5          | 54/F    | Lymph nodes, skin | 12 | None | Clarithromycin, ciprofloxacin | (1) Imipenem/4 (2) Imipenem/4 (3) Imipenem/4 (4) Imipenem/4 | 17 | 1 : 100,000 | 1 : 1,000 | 28 | | Response: stable on NTM treatment without hospitalization for parenteral antibiotic |
| 6          | 65/M    | Lymph nodes, lung, femur | 48 | Salmonellosis | Clarithromycin, ciprofloxacin | (1) Imipenem/4 (2) Imipenem/4 (3) Imipenem/4 (4) Imipenem/4 | 17 | 1 : 100,000 | 1 : 5,000 | 44 | | Response: stable on NTM treatment without hospitalization for parenteral antibiotic |
| 7          | 34/M    | Lymph nodes, lung, multiple bones | 15 | Cryptococcosis, tuberculosis bone | Clarithromycin, ciprofloxacin, linezolid | (1) Imipenem/2 (2) Imipenem/2 (3) Imipenem/4 (4) Imipenem/4 (5) Imipenem/4 (6) Imipenem/4 | 25 | 1 : 200,000 | 1 : 50,000 | 45 | | Not response: relapsed with hospitalization for parenteral antibiotic |
| 8          | 20/F    | Lymph nodes, skin, lung, liver, spleen, pancreas, humerus | 26 | Cryptococcosis, Herpes zoster | Azithromycin, ciprofloxacin, doxycycline, linezolid | (1) Imipenem/4 (2) Imipenem/4 (3) Imipenem/4 | 20 | 1 : 400,000 | 1 : 50,000 | 41 | | Not response: relapsed twice with hospitalization for parenteral antibiotic |
and #3) had complete remission and were able to discontinue the NTM therapy while 3 (patients #4, #5, and #6) had stable disease but remained on NTM treatment without the need of hospitalization for parenteral antibiotics. Two (patients #7 and #8) relapsed and needed hospitalization. Patient #7 had enlarged lymph nodes after 12 cycles of IVCY and needed hospitalization for imipenem; after which, he resumed IVCY for another 3 cycles but developed Herpes zoster ophthalmicus which required admission for administration of parenteral acyclovir. He had a persistent enlarged epitrochlear lymph node after 25 cycles of IVCY. Patient #8 had 2 relapses requiring hospitalization for parenteral imipenem.

3.2. Anti-IFN-γ Autoantibody Titers. The anti-IFN-γ Ab titers among the 7 evaluable patients were significantly decreased during treatment. The median initial antibody titer starting at 200,000 then was decreased to 5,000 after 2 years of treatment (P < 0.0001). The median antibody titers started to be significantly reduced 1 month after receiving IVCY (Figure 1). Antibody titer reduction among responsive patients (n = 5) vs. nonresponsive patients (n = 2) was significantly different after 6 months of treatment (median antibody titer was 5,000 and 100,000, respectively) (P = 0.0467). Antibody titer among the responsive patients started at between 100,000 and 200,000 and was reduced to around 5,000 (range, 1,000–10,000). The antibody titer of nonresponsive patients started at between 200,000 and 400,000 and was reduced to between 10,000 and 200,000 after the first year of treatment and to 100,000 after the second year of treatment.

Among the 5 responsive patients, their anti-IFN-γ autoantibody titers were followed for 1 year after completing the IVCY pulse therapy (Figure 2). The median anti-IFN-γ autoantibody titer had increased from 5,000 to 10,000 three months after discontinuation of treatment, albeit the difference was not statistically significant. The median titers remained stable for up to 12 months.

4. Discussion

Our patients had extensive disease as a result of M. abscessus infection, which progressed over the years: the median duration of infection was 17 months. All of the patients had lymphadenitis along with other sites of M. abscessus infection (Table 1). All but two had coinfection with other opportunistic infections. The patients were refractory to antimycobacterial treatment, so we sought an adjunctive immunotherapy. Rituximab has been used in AOID patients associated with mycobacterial infection with clinical improvement [22–25]; among 7 patients reported, they...
received 4–18 cycles of rituximab over 1–5 years of treatment. Since rituximab is not accessible in our setting, we tried to treat our AOID patients with an available immunosuppressant drug. We used an IVCY regimen resembling the Euro-Lupus protocol for lupus nephritis in combination with a single pulse of methyl prednisolone followed by a moderate dose of prednisolone for the first 3 months and maintenance with low-dose corticosteroid until the end of study. We treated only patients who had a protracted clinical course, defined as having received ≥3 courses of parenteral antibiotic within 12 months. We started the IVCY treatment regimen at the end of the parenteral therapy after the disease was controlled.

Among the 7 evaluable cases, 5 had a clinical response. To date, in two of our patients, the M. abscessus infection was cleared, and the patients were able to discontinue NTM treatment. Three of the remaining patients had stable disease and continued treatment for M. abscessus without needing to be hospitalized for parenteral therapy. Only 2 patients did not respond; they relapsed and needed hospitalization for imipenem therapy.

We demonstrated that IVCY reduced IFN-γ Ab titers significantly. Among the 7 patients studied, the median initial titers decreased after 2 years of treatment (P < 0.0001) and the titers started to decline within one month of receiving IVCY (Figure 1(a)). Comparing between responders and nonresponders, the reduction in Ab titers among responders was significantly greater than that among nonresponders after 6 months of therapy throughout the end of 2 years of therapy (Figure 1(b)). The IFN-γ titers among responders at the end of treatment ranged between 1,000 and 5,000 while for nonresponders’ titers, they averaged 50,000. Our findings suggest that IFN-γ Ab titers are correlated to clinical response; thus, an early drop in IFN-γ titer is a predictor of a good outcome of IVCY treatment. The use of Ab titers to monitor disease activity or to determine when to discontinue antimycobacterial treatment needs further investigation.

Patients #7 and #8 received an extended course of IVCY (25 and 20 cycles, respectively). The lack of clinical improvement suggests that extension of IVCY treatment does not help nonresponders to reduce Ab titers to the level of a responsive titer. Among IVCY nonresponders, switching to other immunosuppressive drugs (i.e., mycophenolate mofetil, azathioprine, or calcineurin inhibitor) may be considered. Importantly, Ab titers among responders were stable up to one year after stopping IVCY therapy.

The present study had some limitations. First, it was a retrospective study, so some information might have been lost. Second, the study had a small sample size but that is partly because AOID is uncommon, and not all cases of anti-IFN-γ autoantibody-mediated disseminated NTM require immunotherapy. Third, we did not identify the isolates of M. abscessus to subspecies level nor identify an inducible macrolide resistance gene which might have effect on the treatment outcomes. Fourth, we did not perform plasma-mediated inhibition of IFN-γ-stimulated STAT-1 phosphorylation; notwithstanding, we previously demonstrated that plasma specimens containing anti-interferon-γ autoantibodies inhibited interferon-γ-induced STAT1 phosphorylation [1]. The Ab titers were correlated to clinical response; thus, we hypothesize that the IFN-γ antibodies in our patients were functioning. Despite these limitations, our results offer valuable clinical information vis-à-vis patients with anti-IFN-γ autoantibody-associated M. abscessus infection who had refractory disease in a resource-limited setting.

In conclusion, IVCY therapy might be an alternative adjunctive immunotherapy for AOID patients infected with M. abscessus and refractory to antimycobacterial treatment since it improved clinical outcomes and reduced the titer of anti-IFN-γ autoantibodies. A rapid decline in the titer of anti-IFN-γ antibody after 6 months of immunosuppressive treatment predicted a good outcome. In cases of a persistently high anti-IFN-γ antibody titer, rather than extending the use of IVCY, the clinician should consider switching to other immunosuppressive drug(s) with different target(s) of action. To avoid serious infection related to the use of long-term cyclophosphamide, a better outcome may be achieved by using a less toxic immunosuppressive drug.

Data Availability
The data used to support the findings of this study are included within the article.

Disclosure
This study has been presented as conference abstract in 28th ECCMID according to the following link: https://www.escmid.org/escmid_publications/escmid_elibrary/material/?mid=64583.

Conflicts of Interest
None of the authors declared conflict of interests relevant for the present work.

Acknowledgments
The authors thank Mr. Bryan Hamman for the assistance with the English-language presentation of the manuscript under the aegis of the Publication Clinic KKU, Thailand. This work has received scholarship under the Post-Doctoral Training Program from Research Affairs and Graduate School, Khon Kaen University, Thailand (Grant no. 59260).

References
[1] S. K. Browne, P. D. Burbelo, P. Chetchotisakd et al., “Adult-onset immunodeficiency in Thailand and Taiwan,” The New England Journal of Medicine, vol. 367, no. 8, pp. 725–734, 2012.
[2] C. Höflich, R. Sabat, S. Rosseau et al., “Naturally occurring anti-IFN-γ autoantibody and severe infections with Mycobacterium chelonae and Burkholderia cœcovenesans,” Blood, vol. 103, no. 2, pp. 673–675, 2004.
[3] R. Döpfner, M. R. Helbert, G. Barcenas-Morales et al., “Autoantibodies to interferon-γ in a patient with selective susceptibility to mycobacterial infection and organ-specific
autoimmunity,” *Clinical Infectious Diseases*, vol. 38, no. 1, pp. e10–e14, 2004.

B. Kampmann, C. Hemingway, A. Stephens et al., “Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-γ,” *The Journal of Clinical Investigation*, vol. 115, no. 9, pp. 2480–2488, 2005.

S. Y. Patel, L. Ding, M. R. Brown et al., “Anti-IFN-γ autoantibodies in disseminated nontuberculous mycobacterial infections,” *Journal of Immunology*, vol. 175, no. 7, pp. 4769–4776, 2005.

Y. Tanaka, T. Hori, K. Ito, T. Fujita, T. Ishikawa, and T. Uchiyama, “Disseminated Mycobacterium avium complex infection in a patient with autoantibody to interferon-γ,” *Internal Medicine*, vol. 46, no. 13, pp. 1005–1009, 2007.

T. Koya, C. Tsubata, H. Kagamu et al., “Anti-interferon-gamma autoantibody in a patient with disseminated Mycobacterium avium complex infection,” *Journal of Infection and Chemotherapy*, vol. 15, no. 2, pp. 118–122, 2009.

B. S. F. Tang, J. F. W. Chan, M. Chen et al., “Disseminated penicilliosis, recurrent bacteraemic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferon,” *Clinical and Vaccine Immunology*, vol. 17, no. 7, pp. 1132–1138, 2010.

T. Kampitak, G. Suwanpimolkul, S. Browne, and C. Suankratay, “Anti-interferon-γ autoantibody and opportunistic infections: case series and review of the literature,” *Infection*, vol. 39, no. 1, pp. 65–71, 2011.

W. I. Lee, J. L. Huang, T. S. Wu et al., “Patients with inhibitory and neutralizing auto-antibodies to interferon-γ resemble the sporadic adult-onset phenotype of mendelian susceptibility to mycobacterial disease (MSMD) lacking Bacille Calmette-Guerin (BCG)-induced diseases,” *Immunobiology*, vol. 218, no. 5, pp. 762–771, 2013.

T. Ishii, A. Tamura, H. Matsu et al., “Disseminated Mycobacterium avium complex infection in a patient carrying autoantibody to interferon-γ,” *Journal of Infection and Chemotherapy*, vol. 19, no. 6, pp. 1152–1157, 2013.

P. Wongkulab, J. Wipasa, R. Chaiwarith, and T. Chaisathaphol and A. Jitmuang, “K. Suzuki, J. Terada, Y. Sasaki et al., “Clinical significance of interferon-γ neutralizing autoantibodies against disseminated nontuberculous mycobacterial disease,” *Clinical Infectious Diseases*, vol. 66, no. 8, pp. 1239–1245, 2018.

C. Y. Chi, C. H. Lin, M. W. Ho et al., “Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections,” *Medicine*, vol. 95, no. 25, article e9327, 2016.

N. Baerlecken, R. Jacobs, M. Stoll, R. E. Schmidt, and T. Witte, “Recurrent, multifocal Mycobacterium avium-intercellulare infection in a patient with interferon-γ autoantibody,” *Clinical Infectious Diseases*, vol. 49, no. 7, pp. e76–e78, 2009.

S. K. Browne, R. Zaman, E. P. Sampaio et al., “Anti-CD20 (rituximab) therapy for anti-IFN-γ autoantibody-associated nontuberculous mycobacterial infection,” *Blood*, vol. 119, no. 7, pp. 3933–3939, 2012.

C. A. Czaia, P. A. Merkel, E. D. Chan et al., “Rituximab as successful adjunct treatment in a patient with disseminated nontuberculous mycobacterial infection due to acquired anti-interferon-γ autoantibody,” *Clinical Infections Diseases*, vol. 58, no. 6, pp. e115–e118, 2014.

N. Pruetoongpun, T. Khaowcharoenporn, P. Damronglerd et al., “Disseminated Talaromyces marneffei and Mycobacteria abscessus in a patient with anti-interferon-γ autoantibodies,” *Open Forum Infectious Diseases*, vol. 3, no. 2, article ofw093, 2016.

Y. Koizumi, T. Sakagami, N. Nishiyama et al., “Rituximab restores IFN-γ-STAT1 function and ameliorates disseminated Mycobacterium avium infection in a patient with anti-interferon-γ autoantibody,” *Clinical Immunology*, vol. 37, no. 7, pp. 644–649, 2017.

H. A. Austin III, J. H. Klippel, J. E. Balow et al., “Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs,” *The New England Journal of Medicine*, vol. 314, no. 10, pp. 614–619, 1986.

F. A. Houssiaux, C. Vasconcelos, D. D’Cruz et al., “Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide,” *Arthritis and Rheumatism*, vol. 46, no. 8, pp. 2121–2131, 2002.

F. A. Houssiaux, C. Vasconcelos, D. D’Cruz et al., “The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide,” *Annals of the Rheumatic Diseases*, vol. 69, no. 01, pp. 61–64, 2009.

M. B. Urowitz, “Is ‘aggressive’ therapy necessary for systemic lupus erythematosus?,” *Rheumatic Diseases Clinics of North America*, vol. 19, no. 1, pp. 263–270, 1993.

C. Yee, C. Gordon, C. Dostal et al., “EULAR randomized controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone...
followed by azathioprine and prednisolone in lupus nephritis,” *Annals of the Rheumatic Diseases*, vol. 63, no. 5, pp. 525–529, 2004.

[31] L. Barile-Fabris, R. Ariza-Andraca, L. Olguín-Ortega et al., “Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus,” *Annals of the Rheumatic Diseases*, vol. 64, no. 4, pp. 620–625, 2005.

[32] M. Calguneri, Z. Ozbalkan, M. A. Ozturk, S. Apras, A. I. Ertenli, and S. Kiraz, “Intensified, intermittent, low-dose intravenous cyclophosphamide together with oral alternate-day steroid therapy in lupus nephritis (long-term outcome),” *Clinical Rheumatology*, vol. 25, no. 6, pp. 782–788, 2006.

[33] R. Giacomelli, G. Valentini, F. Salsano et al., “Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis,” *The Journal of Rheumatology*, vol. 29, no. 4, pp. 731–736, 2002.

[34] P. I. Latsi and A. U. Wells, “Evaluation and management of alveolitis and interstitial lung disease in scleroderma,” *Current Opinion in Rheumatology*, vol. 15, no. 6, pp. 748–755, 2003.

[35] C. P. Simeón-Aznar, V. Fonollosa-Plá, C. Tolosa-Vilella et al., “Intravenous cyclophosphamide pulse therapy in the treatment of systemic sclerosis-related interstitial lung disease: a long term study,” *The Open Respiratory Medicine Journal*, vol. 2, no. 1, pp. 39–45, 2008.

[36] L. Harper, M. D. Morgan, M. Walsh et al., “Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up,” *Annals of the Rheumatic Diseases*, vol. 71, no. 6, pp. 955–960, 2012.

[37] K. de Groot, L. Harper, D. R. Jayne et al., “Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial,” *Annals of Internal Medicine*, vol. 150, no. 10, pp. 670–680, 2009.

[38] K. d. Groot, D. Adu, and C. O. S. Savage, “The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review,” *Nephrology Dialysis Transplantation*, vol. 16, no. 10, pp. 2018–2027, 2001.

[39] M. E. Fleischli, R. H. Valek, and A. G. Pandya, “Pulse intravenous cyclophosphamide therapy in pemphigus,” *Archives of Dermatology*, vol. 135, no. 1, pp. 57–61, 1999.

[40] C. A. Wallace and D. D. Sherry, “Trial of intravenous pulse cyclophosphamide and methylprednisolone in the treatment of severe systemic-onset juvenile rheumatoid arthritis,” *Arthritis and Rheumatism*, vol. 40, no. 10, pp. 1852–1855, 1997.

[41] M. I. Gobbini, M. E. Smith, N. D. Richert, J. A. Frank, and H. F. McFarland, “Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing–remitting multiple sclerosis,” *Journal of Neuroimmunology*, vol. 99, no. 1, pp. 142–149, 1999.

[42] J. S. F. Sanders, M. G. Huurma, C. G. M. Kallenberg, and C. A. Stegeman, “Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment,” *Rheumatology*, vol. 45, no. 6, pp. 724–729, 2006.

[43] A. Sistigui, S. Viaud, N. Chaput, L. Bracci, E. Proietti, and L. Zitvogel, “Immunomodulatory effects of cyclophosphamide and implementations for vaccine design,” *Seminars in Immunopathology*, vol. 33, no. 4, pp. 369–383, 2011.

[44] W. J. McCune and M. B. Clowse, “General principles of the use of cyclophosphamide in rheumatic diseases,” in *UpToDate*, T. W. Post, Ed., UpToDate, Waltham, MA, USA, 2016.

[45] C. Y. Chi, C. C. Chu, J. P. Liu et al., “Anti-IFN-γ autoantibodies in adults with disseminated nontuberculous mycobacterial infections are associated with HLA-DRB1*16:02 and HLA-DQB1*05:02 and the reactivation of latent varicella-zoster virus infection,” *Blood*, vol. 121, no. 8, pp. 1357–1366, 2013.